Clinical Research Directory

Inclusion Criteria: 1. Patients with primary hematological diseases of acute lymphoblastic leukemia, acute myeloid leukemia, or myelodysplastic syndrome who have an indication for allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and are scheduled to undergo myeloablative conditioning; 2. Expected survival ≥ 3 months; 3. Age between 18 and 65 years (inclusive), with no restrictions on sex or race; 4. ECOG performance status ≤ 2; 5. NRS2002 score ≥ 3; 6. The patient, or his/her authorized legal representative, agrees to participate in the clinical trial and signs the informed consent form. Exclusion Criteria: 1. Relapsed and refractory acute myeloid leukemia; 2. Acute myeloid leukemia, myelodysplastic syndrome and acute lymphoblastic leukemia with positive MRD prior to transplantation; 3. Patients with concomitant other malignant tumors requiring treatment; 4. Presence of active infections, such as hepatitis B, hepatitis C, tuberculosis, etc.; 5. Patients with positive HIV serology; 6. Patients with impairment of one or more major organs including heart, lung, liver and kidney, severe abnormal glucose metabolism, or those assessed by the investigator as unable to tolerate treatment; 7. Patients with clinical symptoms of cerebral dysfunction, severe psychiatric disorders, or other conditions rendering them unable to understand or comply with treatment and monitoring requirements; 8. Regular use of enteral nutrition preparations within 1 month prior to study entry; 9. Suspected allergy to the investigational product or any of its excipients; Patients deemed unsuitable for participation by the investigator.